Results 8,181-8,200 of 21,431 for speaker:Alan Kelly

Ceisteanna Eile - Other Questions: Economic Competitiveness (25 Oct 2018)

Alan Kelly: 10. To ask the Minister for Finance his plans to ensure Ireland protects its competitiveness and mitigates the risk of overheating pressures in the economy; and if he will make a statement on the matter. [43972/18]

Written Answers — Department of Finance: Credit Union Advisory Committee (25 Oct 2018)

Alan Kelly: 20. To ask the Minister for Finance the timescale for the conclusion of the Credit Union Advisory Committee's work; when it is next to report to him; the outstanding projects to be completed; and if he will make a statement on the matter. [43973/18]

Ceisteanna ar Sonraíodh Uain Dóibh - Priority Questions: Medicinal Products Reimbursement (23 Oct 2018)

Alan Kelly: 67. To ask the Minister for Health when the agreement with a company (details supplied) will be completed regarding the treatment of 19 alpha 1 clinical trial patients; his plans to extend the treatment to all other alpha 1 patients; the timeline for same; and if he will make a statement on the matter. [43846/18]

Ceisteanna ar Sonraíodh Uain Dóibh - Priority Questions: Medicinal Products Reimbursement (23 Oct 2018)

Alan Kelly: As the Minister will be aware, my neighbour, Ms Marion Kelly, passed away on 1 December last year. She was one of the 21 Alpha-1 patients on the clinical trial for Respreeza. In August 2017, the HSE said that it would not provide reimbursements for this drug. There was then a stand-off for a number of months when two patients, including Marion, passed away having been off the drug for six...

Ceisteanna ar Sonraíodh Uain Dóibh - Priority Questions: Medicinal Products Reimbursement (23 Oct 2018)

Alan Kelly: I appreciate the honesty with which the Minister has addressed the question. Unfortunately, we have been at this juncture for a long time, and it is frustrating. The Minister met the family in April. We had a commitment from the HSE that there was going to be an agreement on the 19 patients quickly. Meetings were supposed to take place quickly but they did not happen. A meeting took...

Ceisteanna ar Sonraíodh Uain Dóibh - Priority Questions: Medicinal Products Reimbursement (23 Oct 2018)

Alan Kelly: I do not want to be here in a month asking the same question on the anniversary of Marion Kelly's passing. She died on 1 December, and she was in my office not long before she passed away. This is important for those who are fighting on behalf of the remaining 19 patients. I also acknowledge the work of Deputy Brassil on this matter. He tabled a parliamentary question to which the...

Written Answers — Department of Health: Medicinal Products Reimbursement (23 Oct 2018)

Alan Kelly: 151. To ask the Minister for Health when Respreeza will be sanctioned fully for persons that took part in the clinical trial; when it will be more widely available to alpha 1 antitripsan patients; and if he will make a statement on the matter. [43274/18]

Written Answers — Department of Health: Oireachtas Joint Committee Reports (23 Oct 2018)

Alan Kelly: 153. To ask the Minister for Health if he has considered the Oireachtas Joint Committee on Health's report on orphan drugs from February 2018; the changes he is considering on foot of same; and if he will make a statement on the matter. [43278/18]

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: I thank the witnesses. Best wishes to Dr. Love in the future. I am sorry to see him go. Best wishes to Paul O'Toole who is taking over his role. I used to work with him many years ago in Bord Fáilte. It is an excellent choice.

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: One might as well be upfront and say when one has worked with somebody. I have personal experience of working with the man. Dr. Love's openness on the issues is very welcome. It will serve us well. I welcome the fact that he is being so upfront on the issues today. It is quite obvious to all members of the committee, who have experience of the issues concerning the HEA, that there is a...

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: I appreciate that.

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: We know about that one.

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: Dr. Love is spot on. That is a fairly accurate and useful comment. Mr. Paul O'Toole is entering the role. Will he be as constrained as Dr. Love was? Are we in a vacuum whereby, from a regulatory point of view, nobody who is ever in Dr. Love's role will be able to deal with the issues in the way this committee expects or the public would require until this legislation is dealt with?

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: This is pretty good stuff. In fairness, the consultative process is going on so we know there is a requirement to do as proposed. Until it is actually dealt with, and because of the Hunt report, the obvious changing role of the HEA and the fact that the legislation does not match up to it, we will not be able to meet the standards required from a regulatory point of view. That is just a fact.

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: It is impossible.

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: So what Dr. Love is saying is that-----

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: I know that and I know exactly what Dr. Love is saying. In his experience, when it comes to governing bodies, there have been glaring examples-----

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: -----where there has been a complete breakdown and it has fallen to the HEA to deal with the mess. However, the HEA does not have the capacity to do so from a legislative point of view. Is that a fair point?

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: This is very revealing. Dr. Love's evidence would mean that we need to speed up this process from a legislative point of view. It should be a priority for the Department. Would Mr. Ó Foghlú agree with that?

Public Accounts Committee: HEA Financial Statements 2017 (18 Oct 2018)

Alan Kelly: In July, we were promised a report from the HEA on Cork Institute of Technology, CIT, companies. I know we have referred to Waterford. Where does that stand-----